Literature DB >> 15536540

Appropriateness of internal digital phantoms for monitoring the stability of the UBIS 5000 quantitative ultrasound device in clinical trials.

D Hans1, I Alekxandrova, C Njeh, C Le-Floch, G Conicella, P Laugier, D O Slosman.   

Abstract

In bone status assessment, proper quality assurance/quality control is crucial since changes due to disease or therapeutic treatment are very small, in the order of 2-5%. Unlike for dual X-ray absorptiometry, quality control procedures have not been extensively developed and validated for quantitative ultrasound technology, limiting its use in longitudinal monitoring. While the challenge of developing an ideal anthropometric phantom is still open, some manufacturers use the concept of the internal digital phantom mimicking human characteristics to check the stability of their device. The objective of the study was to develop a sensitive model of quality control suitable for the correction of QUS patient data. In order to achieve this goal, we simulated a longitudinal device lifetime with both correct and malfunctioning behaviors. Then, we verified the efficiency of digital phantoms in detecting those changes and subsequently established the in vitro/in vivo relationship. This is the first time that an attempt to validate an internal digital phantom has made, and that this type of validation approach is used. The digital phantom (DP) was designed to mimic normal bone (BUAP2) and osteoporotic bone (BUAP1) properties. The DP was studied using the UBIS 5000 ultrasound device (DMS, France). Diverse malfunctions of the UBIS-5000 were simulated. Several series of measurements were performed on both BUAP1 and 2 and on 12 volunteers at each grade of malfunction. The effect of each simulated malfunction on in vivo and in vitro results was presented graphically by plotting the average BUA values against the percentage change from baseline. The change from baseline in BUA was modeled using linear regression, and the in vivo/in vitro ratio was obtained from the model. All experimentations influenced the measure of BUAP1 and 2 as well as the measure of our 12 volunteers. However, the degree of significance varied as a function of the severity of the malfunction, and the results also differed substantially in magnitude between in vivo and in vitro. Indeed, the DP was about 10 times more sensitive to variations of the transfer function than was the in vivo measurement, which is very reassuring. The sensitivity of the digital phantoms was reliable in the determination of simulated malfunctions of the UBIS-5000. The digital phantoms provided an accurate evaluation of the acoustic performance of the scanner, including the fidelity of transducers. In light of these results, the QC approach of the UBIS-5000 will be extremely simple to implement compared with other devices. Indeed, since the digital phantom was automatically measured during every patient measurement, the QC approach could be built on an individual level basis rather than on an average basis.

Entities:  

Mesh:

Year:  2004        PMID: 15536540     DOI: 10.1007/s00198-004-1683-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  12 in total

1.  Longitudinal changes in ultrasound parameters of the calcaneus.

Authors:  P L van Daele; H Burger; C E De Laet; A Hofman; D E Grobbee; J C Birkenhäger; H A Pols
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Ultrasound parametric imaging of the calcaneus: in vivo results with a new device.

Authors:  P Laugier; B Fournier; G Berger
Journal:  Calcif Tissue Int       Date:  1996-05       Impact factor: 4.333

3.  Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts.

Authors:  Y Lu; A K Mathur; B A Blunt; C C Gluer; A S Will; T P Fuerst; M D Jergas; K N Andriano; S R Cummings; H K Genant
Journal:  J Bone Miner Res       Date:  1996-05       Impact factor: 6.741

4.  Ultrasonic measurement: an evaluation of three heel bone scanners compared with a bench-top system.

Authors:  R Strelitzki; A J Clarke; J G Truscott; J A Evans
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

5.  Precision of dual-energy x-ray absorptiometry: development of quality control rules and their application in longitudinal studies.

Authors:  E S Orwoll; S K Oviatt; J A Biddle
Journal:  J Bone Miner Res       Date:  1993-06       Impact factor: 6.741

6.  Quality control of bone densitometry in a national health survey (NHANES III) using three mobile examination centers.

Authors:  H W Wahner; A Looker; W L Dunn; L C Walters; M F Hauser; C Novak
Journal:  J Bone Miner Res       Date:  1994-06       Impact factor: 6.741

7.  Broadband ultrasonic attenuation imaging: a new imaging technique of the os calcis.

Authors:  P Laugier; P Giat; G Berger
Journal:  Calcif Tissue Int       Date:  1994-02       Impact factor: 4.333

8.  Comparison of six calcaneal quantitative ultrasound devices: precision and hip fracture discrimination.

Authors:  C F Njeh; D Hans; J Li; B Fan; T Fuerst; Y Q He; E Tsuda-Futami; Y Lu; C Y Wu; H K Genant
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

9.  Longitudinal quality control methodology for the quantitative ultrasound Achilles+ in clinical trial settings.

Authors:  D Hans; W Wacker; L Genton; E Paris; C Le-Floch; D Slosman
Journal:  Osteoporos Int       Date:  2002-10       Impact factor: 4.507

10.  Good clinical practice and audits for dual X-ray absorptiometry and X-ray imaging laboratories and quality assurance centers involved in clinical drug trials, private practice, and research.

Authors:  B A Blunt; D Jones; R K Svensen; D B Hans; J D Feinblatt; H K Genant
Journal:  J Clin Densitom       Date:  1998       Impact factor: 2.963

View more
  1 in total

1.  The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta.

Authors:  Ingmar Ipach; Torsten Kluba; Petra Wolf; Bertram Pontz; Falk Mittag
Journal:  Orthop Rev (Pavia)       Date:  2012-09-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.